United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$331.59 USD
-5.15 (-1.53%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $331.56 -0.03 (-0.01%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth C Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
UTHR 331.59 -5.15(-1.53%)
Will UTHR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for UTHR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for UTHR
If You Invested $1000 in United Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
UTHR vs. CTLT: Which Stock Is the Better Value Option?
UTHR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term
UTHR vs. CTLT: Which Stock Should Value Investors Buy Now?
Other News for UTHR
United Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024
MannKind Corporation: Finally Gaining Traction
Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today
Pig transplant research yields a surprise: Bacon safe for some people allergic to red meat
Meet some of the world's cleanest pigs, raised to grow kidneys and hearts for humans